옵션 체인은 다양한 행사가격과 만기일에 대한 Eason Technology의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Eason Technology에 대한 시장 심리를 평가합니다..

Eason Technology (AMEX:DXF) 주식, 옵션 체인

Dunxin Financial Hldgs

Eason Technology Ltd Formerly Dunxin Financial Holdings Ltd is engaged in the business of providing loan facilities to micro, small, and medium-sized enterprises and sole proprietors in the Hubei province of the People's Republic of China. It serves family-run businesses, farmers, and individual borrowers. Some of its loan products include Consumer Loans; Commercial Loans; Collateral-Backed Loans; Enterprise Loans, and others.

Eason Technology Limited American Depositary Shares (each representing sixty-thousand (60,000) Ordinary Shares)

Eason Technology Ltd

Dunxin Financial Holdings Ltd ADR

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.schrodinger.com%2F&amp;esheet=54272890&amp;newsitemid=20250612910362&amp;lan=en-US&amp;anchor=Schr%26ouml%3Bdinger&amp;index=1&amp;md5=349784118744a499fb4ec9c3ab73e370">Schrödinger</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in multiple histologies, including in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). These data are being presented in a poster presentation at the European Hematology Association Annual Congress.
"We are very encouraged by the initial results from our Phase 1 study in patients with relapsed/refractory B-cell malignancies. The data presented today, coupled with the differentiated preclinical and safety profiles observed in our previously completed study in healthy volunteers, further increases our conviction about the potential for SGR-1505 to be a best-in-class therapy," said Margaret Dugan, M.D., chief medical officer at Schrödinger. "Dose escalation is complete, and we look forward to discussing these results and our proposed recommended Phase 2 dose with the FDA later this year."
"Despite recent advances in the treatment of B-cell malignancies, resistance to currently available therapies eventually results in treatment failure and disease progression for many patients," said Stephen Spurgeon, M.D., Associate Professor of Medicine, Oregon Health and Science University, and an investigator for the clinical study. "We know that MALT1 plays a critical role in key signaling pathways that drive cancer cell survival and proliferation, making it a promising target for a broad range of B-cell malignancies. Although these data are from an early-phase study, they suggest SGR-1505 demonstrates on-target activity resulting in potential clinical benefit. I look forward to seeing additional data as the study progresses, including response data in patients with aggressive histologies."
"The positive data reported today represent a key milestone for Schrödinger and follow the clinical successes of programs advanced by collaboration partners and companies we have co-founded," said Karen Akinsanya, Ph.D., president, head of therapeutics R&amp;D and chief strategy officer, partnerships at Schrödinger. "These data reinforce the power of Schrödinger's platform to enable the rapid design of differentiated molecules and the impact that our computational approach can have on a drug discovery and development program."
Major Takeaways from the Study
<ul>
<li>As of the data cut-off date, May 13, 2025, 49 patients were enrolled and evaluable for safety, including 18 patients with CLL/SLL, nine with diffuse large B-cell lymphoma (DLBCL), six with Waldenström macroglobulinemia (WM), and five with marginal zone lymphoma (MZL).</li>
<li>Patients had a median of four (range two-nine) prior lines of therapy, with the most common being Bruton's tyrosine kinase (BTK) inhibitors (55.1%), BCL-2 inhibitors (18.4%) and BTK+BCL-2 inhibitors (18.4%).</li>
<li>SGR-1505 was well-tolerated with no dose-limiting toxicities or deaths due to treatment-emergent adverse events (TEAEs). Forty three percent of patients (n=21) experienced ≥ 1 treatment-related adverse event (TRAE), with the most common (≥ 10%) being rash (12%) and fatigue (12%). Ten patients (20%) experienced treatment-emergent serious adverse events (SAEs); one was treatment-related. All blood bilirubin increased TEAEs were asymptomatic, reported in patients with UGT1A1 polymorphisms and none were Grade 4.</li>
<li>Inhibition of IL-2 is a pharmacodynamic biomarker for target engagement and an exploratory endpoint in the study. Preliminary data indicated that SGR-1505 inhibits T-cell derived IL-2 upon ex vivo stimulation achieving the PD target of ~90% inhibition in the majority of PD-evaluable participants treated at ≥ 150 mg QD and all Q12H doses at steady state.</li>
<li>Preliminary efficacy data indicated SGR-1505 was clinically active as a monotherapy in a number of relapsed/refractory B-cell malignancies. Of the 49 participants, 45 patients had at least one follow-up disease assessment or disease progression and were evaluable for preliminary efficacy. The overall response rate (ORR) across all dose levels was 22% (n = 10/45). Thirteen of 49 patients had been on treatment for ≥120 days.
<ul>
<li>Among patients with indolent disease, 3/17 CLL/SLL, 5/5 WM, and 1/5 MZL patients responded. The responses of the three CLL responders were independently reviewed and confirmed, and two had a partial response (PR) with lymphocytosis (PR-L). Two of three CLL patients with partial responses were double-exposed to BTK and BCL-2 inhibitors, and all WM patients were exposed to BTK inhibitors.</li>
<li>The study recently began enrolling patients with aggressive lymphomas into the 300 mg QD and 100 mg Q12H cohorts. A PR was reported in one of four ABC-DLBCL patients.</li>
</ul>
</li>
</ul>

News

SDGR

Schrödinger Reports 22% Response Rate in Early Trial for Drug-Resistant B-Cell Cancers

<ul>
<li>Hippo's Homebuilder Distribution Network Adds 8 New Homebuilders to Westwood's Client Roster; At Closing, Westwood Will Power the Home Insurance Experience for 20 of the Top 25 Homebuilders Representing Over 35% of Total New Single-Family Homes Built in the U.S. Annually &nbsp;</li>
<li>MSI Enters into Program Administrator Agreement and Claims Administration Agreement with Hippo and its Affiliates to Provide Additional Proprietary Capacity to Westwood's Builder Partners &nbsp;</li>
<li>Hippo and its Affiliates, Including Spinnaker, to Provide Fronting Capacity and Additional Reinsurance Support on MSI Programs</li>
</ul>
The Baldwin Group announced today that, Westwood Insurance Agency LLC ("Westwood"), an indirect subsidiary of The Baldwin Group, has entered into an agreement to acquire from Hippo Holdings, Inc. ("Hippo") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) and its affiliates all the outstanding equity interests of the various entities comprising Hippo's homebuilder distribution network. The Partnership, The Baldwin Group's nomenclature for a strategic acquisition, further solidifies Westwood's position as the preeminent insurance agency for the homebuilding industry. Hippo's homebuilder distribution network generated revenues of approximately $29.2million in the most recent trailing 12-month period1 and is expected to deliver approximately $7 million of adjusted EBITDA over the 12 months following the closing of the Partnership, which is currently anticipated to occur on or around July 1, 2025, subject to certain closing conditions. The Partnership is expected to be neutral to Net Leverage (as defined below) and accretive to 2026 pro forma adjusted Diluted EPS.
Separate from the purchase of Hippo's homebuilder distribution network, Millennial Specialty Insurance, LLC ("MSI"), The Baldwin Group's managing general agency (MGA), has entered into a Program Administrator Agreement and a Claims Administration Agreement with an affiliate of Hippo on a new homebuilder program aimed at providing additional proprietary capacity for Westwood's builder partners. Additionally, Hippo and its affiliates, including Spinnaker Insurance Company, have committed to provide capacity and reinsurance support for existing and potential future MSI programs.

BWIN

HIPO

Baldwin Group's Westwood Insurance Agrees To Acquire Homebuilder Distribution Network From Hippo Holdings; Terms Undisclosed

Oshkosh Defense LLC, an Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) business, announced today a three-year contract extension for the Family of Medium Tactical Vehicles A2 (FMTV A2). This award allows the U.S. Army to continue ordering the FMTV A2, including three FMTV A2 Low Velocity Air Drop (LVAD) variants, through February 2028.
&nbsp;
&nbsp;
"The FMTV A2 contract extension enables the Army to continue modernizing its fleet with proven medium tactical vehicles in support of the Army Transformation Initiative and Force Design 2030," said Pat Williams, Chief Programs Officer at Oshkosh Defense. "The FMTV A2 LVAD variants fill a critical capability gap for the Airborne community by replacing an aging fleet with an upgraded capability that can be rapidly deployed in contested and austere environments."
The Oshkosh-designed FMTV A2 fleet delivers critical resupply and proven tactical mobility through a modular architecture developed for increased payload, protection, and mobility with the ability to also seamlessly integrate new and evolving capabilities. Purpose-built to enable dispersed and Multi-Domain Operations (MDO), the FMTV A2 is engineered to incorporate next-generation technologies without compromising operational readiness. Its common platform enhances sustainability, streamlines maintenance, and simplifies lifecycle management.
The award provides the opportunity for continued production and fielding of these mission-critical vehicles into 2030, while preserving a mature U.S.-based supply chain which began with the initial FMTV A1P2 contract in 2009.

Government

Regulations

Oshkosh Defense Lands Army Contract Extension to Keep Supplying Tactical Trucks Through 2028

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

Helius Medical Technologies, Inc, a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona.

HSDT

Helius Medical's PoNSTEP Study Results On PoNS Therapy For MS Gait Improvement Presented At 2025 CMSC Meeting By Shepard Center VP Deborah Backus

GURU Organic Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GURU#TSX">GURU</a>) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 44.44 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $6.50 million which missed the analyst consensus estimate of $8.42 million by 22.85 percent. This is a 18.81 percent decrease over sales of $8.00 million the same period last year.

Earnings

TSX:GURU

GURU Organic Energy Q2 EPS $(0.05), Inline, Sales $6.50M Miss $8.42M Estimate

Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced positive clinical data from the Company's ongoing NX-5948-301 study, a Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory B-cell malignancies.
The data include findings from the fully enrolled Phase 1a dose escalation study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and the ongoing Phase 1a/1b cohorts of patients with Waldenström macroglobulinemia (WM). Talha Munir, M.B. Ch.B, Ph.D., consultant hematologist at Leeds Teaching Hospitals NHS Trust, deputy chair of the United Kingdom National Cancer Research Institute CLL Study Group, and Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, U.K., will present these data at the 30th European Hematology Association Congress (EHA2025), taking place June 12–15, 2025, in Milan, Italy.
"These data demonstrate an impressive safety and efficacy profile for bexobrutideg with improvement in responses in patients over time, including the notable achievement of a complete response in a patient with CLL and a history of two lines of prior therapy who has been on bexobrutideg treatment for over two years," said Dr. Munir. "Patients with relapsed or refractory CLL and WM who have failed treatments with commonly prescribed BTK inhibitors and other agents due to intolerance or acquired resistance have few therapeutic options. Nurix's bexobrutideg has the potential to address this unmet need and provide a life-changing treatment for patients with CLL and WM."
"With longer time on treatment, we are encouraged by the continued favorable safety profile and high ORR with deepening responses in CLL and WM, including those with clinical and genomic high risk features including CNS involvement," said Paula G. O'Connor, M.D., chief medical officer of Nurix. "We have further expanded our Phase 1b cohorts in select CLL populations and remain on track to initiate pivotal studies in 2025."
"Bexobrutideg offers a next-generation approach to BTK targeting with exquisite selectivity, superior preclinical potency, broad coverage of mutations and demonstrated clinical activity in areas of high unmet medical need," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "We are not only preparing to initiate pivotal studies in the coming months but are also laying the foundation for the commercialization of bexobrutideg as a differentiated treatment option for patients with B-cell malignancies."
Data presented at EHA2025 include efficacy and safety findings for patients with CLL/SLL in the fully enrolled Phase 1a dose escalation study (n=48). This cohort of CLL patients was a heavily pretreated population that had received a median of four prior lines of therapy (range = 2–12) including prior covalent BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%), and prior non-covalent BTK inhibitors (27.1%). At baseline, many patients had mutations associated with BTK inhibitor resistance, including mutations in BTK (38.3%) and PLC2G (14.9%). Poor prognostic features were common, including TP53 mutations (44.7%), and five patients (10.4%) had central nervous system (CNS) involvement.
Patients were treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily by oral administration in the Phase 1a dose escalation study. As of the March 12, 2025 data cut, the median follow up was 9.0 months with most patients still on treatment. Bexobrutideg was well tolerated across all doses evaluated with the most common treatment emergent adverse events of purpura/contusion (45.8%), neutropenia (29.2%) and thrombocytopenia (22.9%), primarily low grade. No new onset atrial fibrillation was observed. Among the efficacy evaluable patients with CLL (n = 47), bexobrutideg treatment resulted in a robust objective response rate (ORR) of 80.9% across all doses tested with a median time to first response of 1.9 months. Many patients experienced deepening of their response with longer time, with multiple conversions from stable disease to partial responses and one patient, who has been on treatment for over two years, experienced a complete response. The median duration of response has not been reached, with 18 patients on treatment for more than a year. Responses were observed across all populations regardless of prior treatment, baseline mutations, or CNS involvement.
The data presented at EHA included patients with WM (n=22) treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily by oral administration from both the Phase 1a dose escalation and Phase 1b cohort expansion. Among the 22 WM patients, the median age was 72.5 years (range 58-86 years) and the median number of prior lines of therapy was 3 (range 2-5). All 22 patients previously had been treated with a covalent BTK inhibitor (100%), 21 had received prior chemotherapy/chemo-immunotherapy (95.5%), four had received prior non-covalent BTK inhibitor (18.2%), and one patient (4.5%) had received prior treatment with a BCL2 inhibitor. Baseline mutation status in MYD88 and CXCR4 was captured from patient records. 15 patients (68.2%) had mutations in MYD88, and five patients (22.7%) had mutations in CXCR4. Bexobrutideg was well tolerated in patients with WM with a profile that was consistent with the overall study population and previous disclosures. Adverse events (AEs) were predominantly low grade; with the most common being petechiae (27.3%), diarrhea (22.7%), purpura/contusion (18.2%), neutropenia (18.2%), and thrombocytopenia (18.2%). There were no dose limiting toxicities observed and no grade 5 AEs. Two treatment emergent AEs led to drug discontinuation. No new onset atrial fibrillation was observed.​ As of the March 12, 2025 data cut, 19 patients were evaluable for responses. Objective response was observed in 16 patients (84.2%), including two patients (10.5%) with very good partial response (VGPR), 11 patients (57.9%) with partial response (PR), and three patients (15.8%) with minor response (MR). Three patients (15.9%) had a best response of stable disease (SD). Responses were observed in patients regardless of their baseline mutations in MYD88 and CXCR4. Steady reductions in IgM levels were observed starting from the first assessment at four weeks, which continued to deepen, and three patients achieved IgM reductions of greater than 90%.

NRIX

Nurix Reports 81% Response Rate in CLL Drug Trial, With Complete Remission in Long-Term Patient

New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) ("NEHC" or the "Company"), a next-gen exploration and production platform in the Permian Basin, today announced that Texas Critical Data Centers, LLC ("TCDC") its joint venture with Sharon AI, Inc., is in active discussions with certain large enterprise customers to anchor its planned AI infrastructure buildout in Ector County, Texas. While no formal agreement has been signed, the Company is actively working to align TCDC's Permian Basin AI Infrastructure efforts with the needs of a large-scale, high-performance computing (HPC) development.
 &nbsp;

NEHC

New Era Helium's TCDC JV In Talks With Enterprises For AI Infrastructure Expansion In Texas

I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) ("I-Mab" or the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Listing Rule"). The Company's American Depositary Shares ("ADSs") will continue to be listed and traded on Nasdaq.
To regain compliance with the Listing Rule, the Company's ADSs were required to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved on June 10, 2025. Nasdaq has stated that this matter is now closed.

IMAB

I-Mab Clears Nasdaq's $1 Minimum Bid Rule, Keeps Stock Listing Secure

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082036/10591749643366_.pic_hd-900x600-1.png" alt="" class="wp-image-14314" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082036/10591749643366_.pic_hd-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082036/10591749643366_.pic_hd-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/12082036/10591749643366_.pic_hd-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster earnings
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The drug firm's revenue dropped nearly 22% in the first quarter while net profit fell just over 8%</li>
<li>The ultimate value of the licensing deals, if finalized, would depend on the size of upfront payments and whether milestone goals are met</li>
</ul>
China's pharmaceutical industry has been on a mission to transform itself from a producer of cloned drugs to a global pioneer of new therapies.
As those efforts start to bear fruit, the firms are striking lucrative partnership deals to license their Chinese drugs for development or sale in overseas markets.
CSPC Pharmaceutical Group Ltd.&nbsp;(1093.HK), one of China's top four generic drug makers, is a case in point, illustrating how the sale of selected rights to promising novel drugs is becoming a significant growth engine for the industry.
So much so, that the company chose to tell investors on May 30 that it was in talks on three such tie-ups, even before the deals have been sealed. CSPC Pharma said the transactions under discussion could yield up to $5 billion in initial fees and milestone payments over time, in an&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0530/2025053000193.pdf">announcement</a>&nbsp;that departed from the usual practice of keeping commercial deals under wraps until fully signed off.
Notably, CSPC Pharma chose to flag up the potential for a big pay-off just after it had reported disappointing quarterly earnings, with profits squeezed by price controls in China's national health insurance program.
The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma products, the statement said. The cancer treatment in question is an antibody-drug conjugate that targets the epidermal growth factor protein in tumor cells.
Discussions on one potential transaction have reached an advanced stage and are expected to be finalized later this month, the company said. However, the statement contained multiple caveats reminding investors that the talks were ongoing and no legally binding pacts had yet been agreed.
The transactions, if confirmed, would add to a growing list of CSPC pipelines under joint development or licensing arrangements. The company has already done two partnership deals this year. Last month it disclosed a global licensing pact with BeiGene (688235.SH; 6160.HK) for a drug designed to target cancers through the MTAP enzyme pathway. CSPC Pharma pocketed $150 million upfront and retains the right to up to $135 million in staged development payments and up to $1.55 billion in fees related to sales milestones.
That followed a February deal in which Radiance Biopharma bought European and U.S. rights to develop and commercialize an antibody-drug conjugate targeting the ROR1 protein. Radiance paid $15 million upfront and agreed to $150 million in milestone payments to CSPC Pharma during the drug development and certification stage, as well as $1.08 billion in sales milestone payments and a percentage of revenue.
Based on a headline figure of $5 billion, the three deals on the table would each be worth an average of around $1.7 billion, on a par with the BeiGene collaboration. However, the eventual realized proceeds from each transaction will be determined by the scale of the upfront fees and whether milestones can be achieved.
<h4 class="wp-block-heading">Now for the bad news</h4>
The timing of the announcement suggests a deliberate move to soften the blow from underwhelming quarterly&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0529/2025052900176.pdf">results</a>&nbsp;released on May 29. If so, it had the desired effect. The firm's stock price rose 16.9% over the six trading days after the statement was issued.
In the first quarter, revenue fell 21.91% to 7.02 billion yuan ($976,000) and net profit sank 8.36% to 1.48 billion yuan from the same period a year earlier. Prices of two key products for chemotherapy and blood conditions had to be cut to meet the requirements of China's health insurance scheme. As a result, revenue from finished drugs fell 27.3% to 5.5 billion yuan and income from the oncology business plunged 65.7%.
It was a familiar pattern of sliding turnover and sinking profits, as the company invests heavily in R&amp;D to drive its shift from generic to ground-breaking drugs. In 2024, CSPC Pharma's revenue fell 7.8% from the prior year, while net profit dropped 25.4% to 4.68 billion yuan. In the first quarter of this year, R&amp;D expenses rose 11.4% and accounted for 18.56% of operating revenue. However, the innovative drug business still lacks the economy of scale to serve as a strong revenue driver.
Investors worry that the traditional drug business, as it gradually winds down, will not be able to keep financing the shift into immunotherapy and other novel drugs, pushing the stock price down to HK$4.17 at one point earlier this year.
The prospect of large-scale deals may take the edge off that anxiety, but investors should bear in mind the risk that partnerships can swiftly unravel. VCBeat, a biotech and healthcare-focused information platform, estimates that of 62 licensing deals between Chinese pharmaceutical companies and foreign partners in 2020, at least 25 had been canceled by April this year, a reversal rate of 40%. A deal between CSPC Pharma and Elevation Oncology offers a cautionary tale. Elevation obtained licensing rights over the cancer drug EO-3021 from CSPC Pharma for $27 million upfront and $1.15 billion in milestone payments. However, results of Phase One U.S. clinical trials fell short of the outcome of Chinese tests and Elevation pulled the plug on the project.
Such discrepancies between U.S. and Chinese trials are not uncommon, but the gap reflected poorly on CSPC Pharma.
Its stock is trading at a price-to-earnings (P/E) ratio of around 20 times, much lower than the multiple of 51 for&nbsp;Jiangsu Hengrui Pharmaceuticals&nbsp;(600276.SH; 1276.HK), an industry peer listed in Hong Kong and Shanghai. Developing innovative drugs is a high-stakes, long-haul business. With CSPC Pharma facing a potential funding squeeze, with the generics business slowing and new products still taking off, investors may want to consider watching from the sidelines.

Asia

Biotech

Equities

Opinion

Trading Ideas

CSPC Pharma Pursues Licensing Deals After Lackluster Earnings

Transat A.T. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRZ#TSX">TRZ</a>) reported quarterly earnings of $0.12 per share. This is a 109.92 percent increase over losses of $(1.21) per share from the same period last year. The company reported $1.03 billion in sales this quarter. This is a 5.94 percent increase over sales of $973.20 million the same period last year.

TSX:TRZ

Transat A.T. Q2 EPS $0.12 Up From $(1.21) YoY, Sales $1.03B Up From $973.20M YoY

Sachem Capital Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SACH#NYSE">SACH</a>) (the "Company"), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced that Sachem Capital Corporation Holdings, LLC, an indirect, wholly-owned subsidiary of the Company, consummated a private placement of $100 million aggregate principal amount of five-year Senior Secured Notes due June 11, 2030 (the "Notes") to various institutional investors. An initial draw of $50 million was made at closing, and the remaining $50 million must be drawn by May 15, 2026. The Notes bear interest at a fixed rate of 9.875% per annum, with interest only payable quarterly and a commitment fee of 1.0% on the undrawn portion of the Notes. Payment of the amounts due on the Notes is fully and unconditionally guaranteed by the Company and Sachem Capital Corporation Intermediate, LLC, a wholly-owned subsidiary of the Company. The Notes have received an investment grade rating of A from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.
The Company intends to use the proceeds for a combination of purposes, including the repayment of existing facility balances, the origination of new investments, and to redeem its 7.75% unsecured notes maturing in September 2025.

SACH

Sachem Capital Consummates Private Placement Of $100M Aggregate Principal Amount Of 5-Yr Senior Secured Notes Due June 11, 2030

26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population.
– Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population.
– 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML.

SNDX

Syndax Presents New Revuforj (revumenib) Data In Relapsed/Refractory mNPM1 And NUP98r Acute Leukemia From AUGMENT-101 Trial At EHA 2025

Are robots the solution to China's growing aged care problem? The Chinese Ministry of Industry and Information Technology has announced a large-scale trial program to test whether intelligent machines can provide not just physical assistance, but also emotional support for its expanding senior population.
What Happened: The ministry has invited private companies with proven track records in elder care to apply for the initiative.
Firms must have robust environmental, credit, and safety records to qualify. Selected participants must develop at least 200 robots and deploy them across 20 test sites within two years of approval.
The robots will be evaluated on a wide range of abilities, including cooking, cleaning, and fall prevention, to feeding, lifting, and assisting with going to the toilet, and outdoor mobility.
In addition to physical support, the Ministry has also called for building machines capable of "anti-wandering and anti-falling" features for dementia patients and tools that can identify early symptoms of cognitive decline.
They are also looking for robots that can hold conversations in various dialects, read books and newspapers, and even place video calls to family members. Described as "intelligent communication companion service robots," these machines are expected to counter loneliness and act as possible substitutes for pets.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45899475/craig-federighi-says-building-a-chatbot-was-never-the-goal-promises-apple-intelligences-focus-is-to-meet-you-where-you-are">Craig Federighi Says &#8216;Building A Chatbot&#8217; Was Never The Goal, Promises Apple Intelligence&#8217;s Focus Is To &#8216;Meet You Where You Are&#8217;</a>
Why It Matters: While the ministry does not explicitly call for humanoid design, the features described are most closely associated with human caregiving.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, in an <a href="https://www.beijingchannelnewsletter.com/p/elon-musks-article-in-china-cyberspace">article</a> for China's cyberspace authority in 2022, floated an idea somewhat similar to what the ministry is looking for: &#8220;Perhaps in less than a decade, people will be able to buy a robot for their parents as a birthday gift,&#8221; he wrote, referring to Tesla's humanoid robots currently in development.
Last month, Musk shared his belief that humanoid robots will start impacting countries&#8217; GDPs in "4-5 years." He weighed in on the massive amounts of power humanoid robots will require to function to the height of their capabilities.
Musk has also asserted that Optimus, his company's humanoid robot, is capable of learning tasks simply by <a href="https://www.benzinga.com/markets/equities/25/05/45536080/elon-musk-says-teslas-optimus-can-learn-tasks-by-watching-youtube-videos-just-like-a-human">watching YouTube videos</a>, much like humans can.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang has suggested that Optimus might be the <a href="https://www.benzinga.com/news/25/05/45691451/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo">first humanoid robot to reach both mass production and advanced technical capability</a>. "I think this is likely to be the next multi-trillion-dollar industry," he said.
Recently, Nvidia <a href="https://www.benzinga.com/markets/equities/25/05/45662285/nvidia-unveils-foundation-models-for-humanoids-eyes-era-of-robotics-as-ai-spend-accelerates">unveiled Isaac GR00T</a>, labeled as "the world's first open, fully customizable foundation model for humanoid robots, enabling generalized reasoning and skill development." 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899111/apple-may-end-up-acquiring-perplexity-like-it-did-with-beats-in-2014-says-dan-ives-consumers-need-reasons-to-upgrade-as-iphone-maker-falls-way-behind-in-ai-race">Apple May End Up Acquiring Perplexity Like It Did With Beats In 2014, Says Dan Ives—Consumers Need &#8216;Reasons To Upgrade&#8217; As iPhone Maker Falls &#8216;Way Behind&#8217; In AI Race</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

NVDA

TSLA

Are Robots The Answer To China's Aged Care Crisis? Beijing Launches Massive Trial To Test If Machines Can Cook, Clean And Console The Elderly

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) affirms FY2026 GAAP EPS guidance from $0.80-$1.36 to $0.80-$1.36 vs $1.03 analyst estimate. Affirms FY2026 sales outlook from $700.00 million-$750.00 million to $700.00 million-$750.00 million vs $710.71 million estimate.

Guidance

LOVE

Lovesac Affirms FY2026 GAAP EPS Guidance of $0.80-$1.36 vs $1.03 Est; Affirms FY2026 Sales Guidance of $700.00M-$750.00M vs $710.71M Est

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) is looking for Q2 GAAP EPS of $(0.83)-$(0.58) vs $(0.26) analyst estimate. sees sales of $157.000 million-$166.000 million vs $161.67 million analyst estimate.

Lovesac Sees Q2 GAAP EPS $(0.83)-$(0.58) vs $(0.26) Est; Sees Sales $157.000M-$166.000M vs $161.67M Est

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54272918&amp;newsitemid=20250612347504&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=d564e2f69d9f1c2ea34e8ca51e3ad252">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company's investigational oral CELMoD&#x2122; agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma, as well as the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (LDD) (BMS-986458) in non-Hodgkin lymphoma.
The latest data presented for the three lead CELMoD agents and BCL6 LDD underscore the potential impact that these therapies may have in addressing significant unmet medical needs in hematologic malignancies. These agents are part of continuing research across targeted protein degradation at Bristol Myers Squibb, which also encompasses additional CELMoD agents, LDDs and degrader antibody conjugates (DACs) across blood cancers and solid tumors, as well as non-malignant hematologic disorders.
Protein degraders, like CELMoD agents and LDDs, are therapies designed to target and degrade specific proteins that drive diseases, including many proteins that are difficult to target through conventional small-molecule inhibitors. These innovative agents have the possibility to enhance the efficacy of existing therapies and overcome resistance in various malignancies, potentially improving patient outcomes.

Bristol Myers Squibb Presents Updated Clinical Findings On CELMoD Agents Mezigdomide And Iberdomide In Multiple Myeloma, Golcadomide In Non-Hodgkin Lymphoma, And First Results Evaluating Oral BCL6 LDD In Non-Hodgkin Lymphoma, At EHA 2025

Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.83) by 12.05 percent. This is a 12.05 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $138.37 million which beat the analyst consensus estimate of $137.00 million by 1.00 percent. This is a 4.32 percent increase over sales of $132.64 million the same period last year.

Earnings Beats

Lovesac Q1 EPS $(0.73) Beats $(0.83) Estimate, Sales $138.37M Beat $137.00M Estimate

<ul>
<li>Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy</li>
<li>Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing</li>
<li>Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ("ADSs"), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025</li>
<li>All-stock acquisition has potential to create long-term value for both companies' shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision</li>
<li>Transaction is supported by CureVac's major shareholder dievini Hopp BioTech holding GmbH &amp; Co. KG and certain of its affiliates and expected to close in 2025&nbsp;</li>
</ul>

Large Cap

Health Care

General

BNTX

CVAC

BioNTech Agrees To Acquire CureVac In All-stock Transaction

HC Wainwright &amp; Co. analyst Brandon Folkes assumes Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with a Buy rating and announces Price Target of $7.

Comments

Eason Technology

Eason Technology (DXF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌